Medical artificial intelligence (AI) company Lunit (CEO Seo Beom-seok) announced on the 20th that it will present two research abstracts utilizing its AI biomarker platform, Lunit SCOPE, at the '2025 Society for Immunotherapy of Cancer (SITC 2025)' to be held in Maryland, USA from the 5th to the 9th of next month.
At this conference, Lunit will present the results of a joint research project with global clinical trial organization (CRO) CellCarta in a poster presentation format. Key presentation topics include: ▲Immunophenotyping of non-small cell lung cancer, colorectal cancer, and urothelial cancer using AI-based tumor microenvironment analysis; and ▲AI-based quantitative immunohistochemical (IHC) analysis to elucidate the spatial correlation between tumor-associated antigens and lymphocytes.
Since 2021, Lunit has participated in SITC annually to validate the clinical applicability of AI-based biomarkers. The company's "Lunit Scope" platform, based on AI-based pathology image analysis technologies such as tumor microenvironment analysis and immunophenotypic classification, is expanding its application in the field of immuno-oncology through collaborations with pharmaceutical and biotech companies, contract research organizations (CROs), and specialized cancer medical institutions.
Through this announcement, Lunit plans to emphasize the technological excellence and applicability of the 'Lunit Scope' in predicting immune anticancer treatment responses and establishing patient-tailored treatment strategies.
Seo Beom-seok, CEO of Lunit, said, “Lunit Scope is gradually gaining trust from research institutes and companies around the world and is strengthening its competitiveness in the field of treatment response prediction.” He added, “We will contribute to the realization of precision medicine based on AI technology and contribute to improving the treatment effectiveness of immuno-oncology drugs.”
- See more related articles
You must be logged in to post a comment.